• Organ-On-A-Chip Platform For Studying Immune Response To Vaccines

    Bio-IT World | A first in the world of organs-on-a-chip, researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have come up with a lymphoid follicle (LF) model that can be used to probe the function of the immune system and predict its response to vaccines—including the three (Pfizer, Moderna, and J&J) currently in use for the prevention of COVID-19. “We hit upon the recipe that works and, in retrospect, it makes sense given what happens naturally,” says senior staff scientist Girija Goyal, Ph.D.

    Jun 21, 2022
  • Improving Data Standardization in Neuroscience Research

    Bio-IT World | Recent advances in the commercialization of neuroscience data acquisition technology have enabled a quickly growing collection of massive brain activity and behavioral datasets. Within the data lie exciting promises of solving how the brain generates behavior, and how it might be better healed when diseased or disturbed. But interpreting these large, high-dimensional datasets isn’t easy. We need modern, collaborative solutions that help scale data management, analysis, and knowledge sharing.

    Jun 17, 2022
  • Moving Data for Clinical Trials: Standards, Systems to Link EHRs with EDC

    Bio-IT World | “Thirty to 40% of clinical trial costs are associated with actually just the manual retyping of [EHR] data [into the clinical trial system], and it leads to reporting delays and a number of other inefficiencies,” Adam Asare, chief data officer at the Quantum Leap Healthcare Collaborative/UCSF, told the Bio-IT World Conference & Expo audience last month. Asare shared a solution to that problem: a collaboration with OpenClinica that won the team a Bio-IT World Innovative Practices Award.

    Jun 16, 2022
  • Tag Technology Helps Drugmakers Assess If ‘The Juice Is Worth The Squeeze’

    Bio-IT World | While the field of targeted protein degradation (TPD) continues its rapid expansion, with multiple TPD drugs now in clinical trials, researchers in Australia are jumping in at an earlier stage with “tag technology” to ensure the disease protein is worth designing a drug against in the first place. Their work—an extension of other tag-targeting protein degradation technologies—gives researchers the wherewithal to ask if, “the juice is worth the squeeze,” according to Rebecca Feltham, Ph.D., laboratory head in the Ubiquitin Signalling Division of the Walter and Eliza Hall Institute.

    Jun 15, 2022
  • ‘Federated Analysis’ Helps Fill Genetic Risk Knowledge Gap On BRCA Genes

    Bio-IT World | A significantly heightened risk of breast cancer has two well-known culprits—mutations to the tumor suppressor genes BRCA1 and BRCA2—but more than 40% of the time they are black-box “variants of uncertain significance.” Using a new data-sharing innovation known as federated analysis, however, an international team of researchers has categorized 16 of these uncertain variants as benign or likely benign so their carriers may be able to have their clinical risk of disease managed properly and avoid the risk of invasive and irrevocable surgeries.

    Jun 14, 2022